a protease inhibitor drug approved for the treatment of late-stage HIV disease. Current practice favors the use of indinavir in combination therapy (e.g., with nucleoside analog drugs) to avoid the development of drug-resistant virus.

Indications: Treatment of HIV infection in combination with other agents. Contraindications: Known hypersensitivity. Dosage: 800 mg po q8h on an empty stomach or with a non-fat meal. Patients should drink at least 48 ounces of fluid a day. Of note, bid dosing has decreased efficacy and should be avoided. When coadministered with ritonavir (100-200 mg po bid) as pharmacologic booster, dose is 800 mg po bid without food restrictions. There are many potential drug interactions, some of which require dosage modification; see Physicians Desk Reference or package insert for more information. Toxicity: Nephrolithiasis, gastrointestinal intolerance, hyperbilirubinemia. Pregnancy category C.

Protease inhibitor for use in combination with other antiretroviral agents for the treatment of HIV infection; also known as IDV. Generic name for Crixivan®.

Indinavir (IDV) (trade name Crixivan®) (Merck) is a protease inhibitor used as a component of highly active antiretroviral therapy (HAART) to treat HIV infection and AIDS.